Real-World Study
Shows ZEPATIER® (Elbasvir and Grazoprevir) Resulted in High
Rates of Sustained Virologic Response in Patients with Chronic Hepatitis C
Infection Who Have Chronic Kidney Disease
Observational Analysis
Evaluated Patients in U.S. Veterans Affairs System
KENILWORTH, N.J., Oct. 21,
2017 – Merck (NYSE: MRK), known as MSD outside of the United States
and Canada, today announced the presentation of findings from a retrospective
database analysis of patients with chronic hepatitis C virus (HCV) genotype
(GT) 1 or 4 infection who have chronic kidney disease (CKD) and were treated
with ZEPATIER® (elbasvir and grazoprevir) in the U.S.
Department of Veterans Affairs (VA) healthcare system. Among patients who
completed therapy, the analysis showed 95.6 percent (714/747) of patients with
severe CKD (stages 4-5, defined as estimated glomerular filtration rate (eGFR)
<30 mL/min/1.73 m2) and 97.1 percent (758/781) of patients with
moderate CKD (stage 3, defined as eGFR 30-59 mL/min/1.73 m2)
achieved sustained virologic response (SVR), defined as HCV RNA below the limit
of quantification at least 10-12 weeks after the end of treatment. For patients
with missing HCV RNA data after at least 10-12 weeks after treatment
completion, analyses were conducted on a post-hoc basis using the last HCV RNA
data available after week 4 after therapy completion. The response rates in the
real-world setting of the VA further supplement findings from controlled clinical studies of ZEPATIER. These
findings will be presented today at The Liver Meeting® 2017 taking place
in Washington, D.C.
Anexo:
0 comentários:
Postar um comentário